-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Camrelizumab is a PD-1 monoantigen antibody independently developed by Hengrui Pharmaceuticals in China.
listed in China in 2019 after two approved adaptations: relapsed/resuscidable Hodgkin's lymphoma and advanced hepatocellular carcinoma.
On June 19, 2020, Karelli pearl single resistance added two approved adaptation disorders: 1) combined with Pymetroser and carabin for first-line treatment of advanced or metastatic non-squamous non-small cell lung cancer;
recently, Chinese researchers published the results of the latest clinical trial of Karelli's pearl monoantigen in the journal Journal of Clinical Oncology: the efficacy of carelli's monoantigen in the treatment of advanced cervical cancer.
the trial is a multi-center, open-label one-arm Phase II trial that recruits patients with advanced cervical cancer who have previously progressed after at least first-line system treatment.
200 mg/2 weeks and apatinist 250 mg/day for treatment.
end point is the Objective Mitigation Rate (ORR).
secondary endpoints are progress-free survival (PFS), total survival (OS), and mitigation duration and safety.
45 patients were recruited for research treatment.
51.0 years of age and 57.8% of patients had previously received second-line or above chemotherapy for relapsed or metastasis courses.
10 patients (22.2%) were treated with beval monoantin.
11.3 months of medium duration follow-up and 55.6 percent of ORR, including two cases of complete remission and 23 partial remissions.
PFS is 8.8 months.
mitigation mid-duration and mid-OS are achieved.
3/4 adverse reactions (AE) associated with overall survival without progression occurred in 71.1% of patients, with the most common AE being hypertension (24.4%), anemia (20.0%) and fatigue (15.6%).
most common potential immune-related AEs include 1-2 levels of hypothyroidism (22.2%) and reactive skin capillary endoblastic cell hyperplocysis (8.9%).
, Karelli's monoantigen apatinist showed encouraging anti-tumor activity and controlled toxicity in patients with advanced cervical cancer.
can be validated in larger randomized controlled trials in the future.
.
